Background
Selank was originally designed as a tuftsin analog — tuftsin being an endogenous tetrapeptide with known immunostimulatory properties. While Selank’s anxiolytic properties were the primary focus of clinical development, its tuftsin-like scaffold suggested potential immunomodulatory effects that had not been systematically characterized.
This study directly tested Selank’s effects on cytokine production in human immune cells, providing mechanistic grounding for the connection between its anxiolytic and immune effects — a relationship consistent with the known bi-directional HPA-immune axis.
Key Findings
Pro-inflammatory Cytokine Suppression (LPS-stimulated PBMCs):
- Selank (10⁻⁸ to 10⁻⁶ M) dose-dependently reduced LPS-induced IL-6 secretion (−35% at 10⁻⁶ M, p < 0.01)
- TNF-α secretion similarly reduced (−28% at 10⁻⁶ M)
- Effects were concentration-dependent with an inverted-U dose-response consistent with hormesis
Adaptive Immune Enhancement:
- IL-2 (T-cell growth factor) production modestly increased in unstimulated PBMCs
- IFN-γ (Th1/cytotoxic T-cell cytokine) upregulated — suggesting promotion of cell-mediated immunity
- NK cell activity: tendency toward enhancement, though not reaching statistical significance in this preparation
Mechanism Hypothesis:
| Cytokine | Selank Effect | Proposed Significance |
|---|---|---|
| IL-6 ↓ | Anti-inflammatory | HPA axis dampening, anxiety reduction |
| TNF-α ↓ | Anti-inflammatory | Neuroprotection, mood stabilization |
| IL-2 ↑ | Immunostimulatory | Adaptive immune support |
| IFN-γ ↑ | Immunostimulatory | Antiviral/antitumor defense |
Clinical Significance
The dual anxiolytic + immunomodulatory profile positions Selank uniquely compared to conventional anxiolytics:
- Stress-immune axis: Chronic anxiety is associated with elevated pro-inflammatory cytokines (IL-6, TNF-α); Selank’s simultaneous anxiolytic and cytokine-suppressing activity could interrupt this feedback loop
- Infections and anxiety comorbidity: For patients with anxiety alongside immune vulnerability, Selank’s IL-2/IFN-γ enhancement could be beneficial where benzodiazepines (which are immunosuppressive) would worsen immune function
- Mechanistic bridge: Understanding that Selank modulates cytokines explains the reported improvements in cognitive function — IL-6 and TNF-α are known to impair neurogenesis and synaptic plasticity at elevated levels
Limitations
- In vitro study with human PBMCs — complex in vivo immune regulation involves many additional variables
- Concentrations tested may not accurately reflect tissue concentrations after intranasal Selank administration
- No human clinical immune endpoint studies confirming these in vitro findings
- Selank’s primary receptor target for cytokine modulation has not been definitively identified